Regulus, AstraZeneca Deal Rekindles Interest in RNA
By Catherine Shaffer
Thursday, August 16, 2012
Regulus Therapeutics Inc., of La Jolla, Calif., inked another two deals related to its microRNA technology. Its agreement with London's AstraZeneca plc calls for a $28 million up-front cash and equity payment, plus milestones, for development of three microRNA targets.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.